Savara Inc

SVRA

Healthcare|Biotechnology|USA

$6.03

-0.26 (-4.06%)

Tangible Book

$0.80

Earnings Power

$0.88

About

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Stock Price

+162.2%(1Y)

Pipeline Summary

14 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 8Recruiting: 1Active: 1AVAILABLE: 1Terminated: 2Withdrawn: 1

Active Trials (2)

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).

NCT06431776Autoimmune Pulmonary Alveolar Proteinosis

Phase 3Recruiting

Enrollment: 5 participants

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293Autoimmune Pulmonary Alveolar Proteinosis

Phase 3Active

Enrollment: 164 participants

BioScore

4.9/10

Cautious

Ownership

Recent Insider Trades

Lowrance David LSELL

2026-06-22394,528 shares @ $5.68

RAMSAY DAVID ASELL

2025-12-1920,000 shares @ $6.06

Hawkins Richard JBUY

2025-06-2048,225 shares @ $2.04

McCracken Joseph SBUY

2025-05-2910,000 shares @ $2.08

RAMSAY DAVID ABUY

2025-03-31150,000 shares @ $2.78

Data last updated: Jul 13, 2026, 12:47 PM